(Reuters) - AbbVie Inc reported a 24 percent jump in quarterly profit due to higher sales of its arthritis drug, Humira, and the inclusion of sales of Pharmacyclics' blood cancer drug, Imbruvica.
ABBVIE (ABBV.NY)s net profit rose to $1.37 billion, or 83 cents per share, in the second quarter ended June 30 from $1.10 billion, or 68 cents per share, a year earlier.
Revenue rose 11 percent to $5.48 billion.
AbbVie completed the acquisition of Pharmacyclics on May 26, giving it about one month's revenue from Imbruvica.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)
Relacionados
- Abengoa B fracasa en su reordenación alcista
- Fracasa diálogo para apaciguar región boliviana en huelga
- El Parlamento libanés fracasa en su 26º intento de nombrar a un nuevo presidente
- El Parlamento de Líbano fracasa por 26ª vez en su intento de nombrar a un nuevo presidente
- Sampaoli: "Si la idea fracasa será responsabilidad nuestra"
